Bio-Rad Laboratories, Hercules, Calif, has launched a range of recombinant monoclonal antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).
Ranibizumab is used in the treatment of diabetic retinopathy, macular edema, and wet, age-related macular degeneration, a common form of age-related vision loss. The anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target-complex specific antibodies, and are designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and biosimilars.
Amanda Turner, Bio-Rad Laboratories.
“We are excited to introduce four anti-ranibizumab antibodies that are highly specific for ranibizumab or the ranibizumab-VEGF-A complex,” says Amanda Turner, product manager in the life science group at Bio-Rad. “Ranibizumab is a Fab fragment drug and is present at very low levels in patient samples, which presents challenges for PK assay design and sensitivity. The high-affinity ranibizumab-VEGF complex-specific antibody is unique to Bio-Rad and overcomes those challenges by enabling the development of a PK antigen capture assay to measure free drug.”
Bio-Rad’s anti-idiotypic antibodies are generated using the company’s human combinatorial antibody library and CysDisplay, a proprietary method of phage display with guided selection methods for producing highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.
The anti-ranibizumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.
For more information, visit Bio-Rad Laboratories.
